The placebo effect: How a new FDA rule could pile more strain onto vaccine developers

The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.

By Alexandra Pecci • May 20, 2025

Regeneron wins bid to buy 23andMe out of bankruptcy

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

By Ned Pagliarulo • May 20, 2025

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

A startup with Theranos ties has another blood test in the works. This time, competition is waiting.

A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.

By Meagan Parrish • May 16, 2025

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

By Michael Gibney • May 15, 2025

Women’s health faces growing headwinds, despite jump in venture investment

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.

By Delilah Alvarado • May 14, 2025

Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy

But the therapies will need to prove their worth in the clinic over the next few years.

By Kelly Bilodeau • May 12, 2025

AI is already delivering pharma value — and not just in drug discovery

While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.

By Meagan Parrish • May 12, 2025

RFK Jr.’s autism fixation hearkens back to his stance on vaccines

The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.

By Amy Baxter • May 9, 2025

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

By Michael Gibney • May 8, 2025

Prasad’s FDA appointment pressures cell and gene therapy stocks

A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

By Ben Fidler • May 7, 2025

After an up and down year, pharma’s R&D landscape is shifting again

While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

By Kelly Bilodeau • May 5, 2025

With compounders out of the way, Lilly and Novo go after each other

The two obesity leaders are pulling on all levers to stay on top of the market.

By Amy Baxter • May 5, 2025

Is pharma ready to let go of animal testing?

Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.  

By Meagan Parrish • May 2, 2025

Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding. 

By Michael Gibney • May 1, 2025

US backlash against mRNA vaccines could hinder scientific progress

U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.

By Michael Gibney • April 29, 2025

Will Cobenfy’s clinical stumble derail a once-predicted rise?

BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.

By Kelly Bilodeau • April 28, 2025

What’s being cut at NIH

A look at the government’s far-reaching rollback in research grants so far.

By Meagan Parrish • April 25, 2025

Flagship’s latest venture reflects more than 25 years of leaping into the unknown

A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

By Michael Gibney • April 24, 2025

Genetic breakthroughs could point pharma to a long COVID drug

The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

By Kelly Bilodeau • April 22, 2025

Can anything threaten Novo and Lilly’s obesity market dominance?

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

By Amy Baxter • April 21, 2025

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

By Alexandra Pecci • April 21, 2025

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

By Meagan Parrish • April 18, 2025

Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

By Alexandra Pecci • April 16, 2025

US risks losing biotech edge to China, report warns

“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

By Ned Pagliarulo • April 9, 2025

Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape

The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ROI.

By Alexandra Pecci • April 9, 2025